Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Seattle Genetics Extends Agensys Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Seattle Genetics Extends Agensys Alliance

To co-develop additional antibody-drug conjugate

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Seattle Genetics, Inc. has exercised an option to co-develop an additional antibody-drug conjugate (ADC), ASG-15ME, under its existing collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma. ASG-15ME targets the tumor antigen SLITRK6, which is expressed on bladder and lung cancer. Agensys has submitted an IND to the FDA for a Phase I trial of ASG-15ME. Seattle Genetics will make a payment and thereafter fund half of the future development costs for the ASG-15ME program.
 
 “Through our collaboration and co-development agreements with companies like Agensys/Astellas, Seattle Genetics continues to enhance its ability to innovate by combining our industry-leading ADC technology with proprietary cancer targets and antibodies to develop potential new treatments for patients with cancer,” said Eric L. Dobmeier, chief operating officer of Seattle Genetics. “ADCs represent a novel therapeutic approach, and through our pipeline and collaborations more than half of the ADC candidates in clinical development utilize our technology. We look forward to working with Agensys/Astellas to advance ASG-15ME.” 
 
 “We’re eager to continue our strong collaboration with Seattle Genetics for ASG-15ME,” said David Stover, Ph.D., senior vice president, Agensys Site Head. “This collaboration with Seattle Genetics is in line with our goal to utilize the most advanced technologies to generate more innovative medicines in oncology.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics